1. Introduction
1.1 Report Description
1.2 Research Methodology
1.2.1 Data Mining
1.2.2 Market Modeling and Forecasting
1.2.3 Data Validation
1.2.4 Industry Analysis
 

2. Market Dashboard
 

3. Market Overview
3.1 Market Definition and Scope
3.2 Market Segmentation
3.2.1 By Treatment Types
•    Disease-Modifying Therapies (DMTs)
o    Amyloid-Targeting Agents
    Monoclonal Antibodies
    Small Molecule Inhibitors
    Others
o    Tau Protein Modulators
    Anti-Tau Monoclonal Antibodies
    Tau Aggregation Inhibitors
o    Neuroinflammation Modulators
    Anti-Inflammatory Agents
    Microglial Modulators
o    Others
•    Symptomatic Treatments
o    Cognitive Enhancers
    Cholinesterase Inhibitors
    NMDA Receptor Antagonists
o    Neuropsychiatric Symptom Treatments
    Antidepressants
    Antipsychotics
o    Adjunctive Therapies
    Nutritional Supplements
    Lifestyle Interventions
o    Others
3.2.2 By Patient Demographics
•    Elderly Patients (65+ years)
•    Early-Onset Alzheimer’s (Under 65 years)
•    Genetic Risk Group
3.2.3 By Diagnostic Tools
•    Imaging Techniques
o    Positron Emission Tomography (PET)
    Amyloid PET Imaging
    Tau PET Imaging
o    Magnetic Resonance Imaging (MRI)
    Structural MRI
    Functional MRI
o    Others
•    Biomarker Assays
o    Cerebrospinal Fluid (CSF) Biomarkers
o    Blood-Based Biomarkers
o    Others
•    Genetic Testing
o    APOE Genotyping
o    Familial Alzheimer’s Gene Panels
o    Others
3.2.4 By Distribution Channels
•    Hospitals & Clinics
o    Neurology Clinics
o    Memory Care Centers
•    Retail Pharmacies
o    Chain Pharmacies
o    Independent Pharmacies
•    Online Pharmacies
3.2.5 By Therapeutic Applications
•    First-Line Treatment
o    Cholinesterase Inhibitors
o    NMDA Receptor Antagonists
o    Lifestyle-Based Interventions
•    Disease Progression Treatment
o    Monoclonal Antibodies
o    Combination Therapies
•    Refractory Alzheimer’s Disease
o    Experimental Therapies
o    Adjunctive Symptom Management
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Restraints
3.3.3 Opportunities
3.3.4 Challenges
 

4. United States Alzheimer’s Disease Market by Treatment Types
4.1 Introduction
4.2 Market Size and Growth Rate by Treatment Types (2024-2030)
4.2.1 Disease-Modifying Therapies
•    Amyloid-Targeting Agents
•    Tau Protein Modulators
•    Neuroinflammation Modulators
4.2.2 Symptomatic Treatments
•    Cognitive Enhancers
•    Neuropsychiatric Symptom Treatments
•    Adjunctive Therapies
 

5. United States Alzheimer’s Disease Market by Patient Demographics
5.1 Introduction
5.2 Market Size and Growth Rate by Patient Demographics (2024-2030)
5.2.1 Elderly Patients (65+ years)
5.2.2 Early-Onset Alzheimer’s (Under 65 years)
5.2.3 Genetic Risk Group
 

6. United States Alzheimer’s Disease Market by Diagnostic Tools
6.1 Introduction
6.2 Market Size and Growth Rate by Diagnostic Tools (2024-2030)
6.2.1 Imaging Techniques
6.2.2 Biomarker Assays
6.2.3 Genetic Testing
 

7. United States Alzheimer’s Disease Market by Distribution Channels
7.1 Introduction
7.2 Market Size and Growth Rate by Distribution Channels (2024-2030)
7.2.1 Hospitals & Clinics
7.2.2 Retail Pharmacies
7.2.3 Online Pharmacies
 

8. United States Alzheimer’s Disease Market by Therapeutic Applications
8.1 Introduction
8.2 Market Size and Growth Rate by Therapeutic Applications (2024-2030)
8.2.1 First-Line Treatment
8.2.2 Disease Progression Treatment
8.2.3 Refractory Alzheimer’s Disease
 

9. Competitive Landscape
9.1 Company Profiles
9.1.1 Biogen Inc. (United States)
•    Business Overview
•    Product Portfolio
•    Strategic Developments
•    Financial Overview
9.1.2 Eli Lilly and Company (United States)
9.1.3 Eisai Co., Ltd. (Japan)
9.1.4 Roche Holding AG (Switzerland)
9.1.5 Novartis International AG (Switzerland)
9.1.6 Pfizer Inc. (United States)
9.1.7 Merck & Co., Inc. (United States)
9.1.8 Johnson & Johnson (United States)
9.1.9 AbbVie Inc. (United States)
9.1.10 AstraZeneca plc (United Kingdom)
9.1.11 Amgen Inc. (United States)
9.1.12 GlaxoSmithKline plc (United Kingdom)
9.1.13 Sanofi S.A. (France)
9.1.14 Takeda Pharmaceutical Company Limited (Japan)
9.1.15 Cassava Sciences, Inc. (United States)
 

10. Conclusion and Recommendations
 

11. Appendix
11.1 List of Tables
•    Market Size of United States Alzheimer’s Disease Market (2024–2030)
•    Segmentation Breakdown of United States Alzheimer’s Disease Market
•    List of Approved and Pipeline Alzheimer’s Drugs
•    Key Market Players and Their Market Share
•    Distribution Channels and Revenue Contribution
 

11.2 List of Figures
•    Alzheimer’s Disease Market Size and Forecast (2024–2030)
•    Market Segmentation by Treatment Type
•    Growth Trends in Disease-Modifying Therapies
•    Market Share of Leading Pharmaceutical Companies
•    Adoption Rate of Diagnostic Technologies

Research Methodology      

The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done, and new Information is again incorporated into data model. The process continues till desired level of Information is not generated

To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.

Secondary Research

The secondary research source that are typically referred to include, but are not limited to:

• Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
• Internal and external proprietary databases, relevant patent and regulatory databases
• National government documents, statistical databases and market reports
• News articles, press releases and web-casts specific to the companies operating in the market

The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista

• Inner Circle Represents – Stage of Research Process
• Middle Circle Represents – Source of Information
• Outer Circle Represents – Information Derived from that source    

Primary Research
We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:                
 

• It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc.                        
• Helps in validating and strengthening the secondary research findings
• Further develops the analysis team’s expertise and market understanding
• Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
   

The participants who typically take part in such a process include, but are not limited to:
 

• Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers
• Purchasing managers, technical personnel, distributors and resellers
• Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets 
• Key opinion leaders specializing in different areas corresponding to different industry distribution channels

Models
Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
 

• Demographic data: Population split by segment
• Macro-economic indicators: GDP, etc.
• Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities.
• Data is then cross checked by the expert panel.

2..1    Company Share Analysis Model

Company share analysis is used to derive the size of United States market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps: 
2..2    Revenue Based Modeling

Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.

2.1    Research Limitations
Inflation is not a part of pricing in this report. Prices of United States Alzheimer’s Disease Market and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Globally. Regional average price has been considered while breaking down this market by application in each region.
This report provides market size of United States Alzheimer’s Disease Market for the past year and forecasts for the next six years. United States Alzheimer’s Disease Market size is given in terms of revenue Market revenue is defined in USD Million. Market numbers are given on the basis of different United States Alzheimer’s Disease Market categories. Market size and forecasts for each major application is provided in the context of Global market. The numbers provided in this report are derived on the basis of demand for United States Alzheimer’s Disease Market from different application industries in different regions.

Segmentation
Therapeutic Approaches
•    Disease-Modifying Therapies (DMTs)
o    Amyloid-Targeting Agents
    Monoclonal Antibodies
    Lecanemab
    Donanemab
    Others
    Small Molecule Inhibitors
    BACE Inhibitors
    Gamma-Secretase Inhibitors
    Others
o    Tau Protein Modulators
    Anti-Tau Monoclonal Antibodies
    Tau Aggregation Inhibitors
o    Neuroinflammation Modulators
    Anti-Inflammatory Agents
    Microglial Modulators
o    Others
•    Symptomatic Treatments
o    Cognitive Enhancers
    Cholinesterase Inhibitors (Donepezil, Rivastigmine)
    NMDA Receptor Antagonists (Memantine)
    Others
o    Neuropsychiatric Symptom Treatments
    Antidepressants
    Antipsychotics
o    Adjunctive Therapies
    Nutritional Supplements
    Lifestyle Interventions
o    Others
 

Diagnostic Tools
•    Imaging Techniques
o    Positron Emission Tomography (PET)
    Amyloid PET Imaging
    Tau PET Imaging
o    Magnetic Resonance Imaging (MRI)
    Structural MRI
    Functional MRI
o    Others
•    Biomarker Assays
o    Cerebrospinal Fluid (CSF) Biomarkers
    Amyloid Beta Levels
    Tau Protein Levels
o    Blood-Based Biomarkers
    Plasma Amyloid Beta
    Neurofilament Light Chain (NfL)
o    Others
•    Genetic Testing
o    APOE Genotyping
o    Familial Alzheimer's Gene Panels
o    Others